Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Austin, Texas


Purpose:

This study is an extension of a study that has been ongoing for 1 year. The purpose of this open label study is to see the how well type 2 diabetics respond to VI-0521(phentermine/topiramate) in controlling blood sugar and how safe VI-0521 is over an extended period of time. All subjects eligible to enroll into this study will receive study drug.


Criteria:

Inclusion Criteria: - Have completed the qualifying DM-230 trial - If females of child-bearing potential, subjects must be using adequate contraception - Provide written informed consent - Be willing and able to comply with scheduled study visits, treatment plan, lab tests and other study procedures - Be greater than 80% compliant in study medication use during the last three visits for DM-230 Exclusion Criteria: - Subjects who have developed one or more morbidities during the DM-230 trial that would pose a safety concern


NCT ID:

NCT00737633


Primary Contact:

Study Director
Barbara Troupin, MD, MBA
VIVUS, Inc.


Backup Contact:

N/A


Location Contact:

Austin, Texas
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.